Physician profile
Francis Nardella
NPI 1780735571
$3,433.76
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $1,091 · 2021: $846 · 2022: $935 · 2023: $240 · 2024: $26.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $266.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,189.86 | 2020-2022 | |
| Amgen INC. | $676.20 | 2019-2023 | Otezla, Enbrel, Tavneos |
| Janssen Biotech, INC. | $479.49 | 2020-2024 | Remicade, Stelara, Simponi Aria |
| Genentech USA, INC. | $221.92 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $203.72 | 2021-2023 | Acthar |
| Abbvie INC. | $132.05 | 2019-2022 | |
| Glaxosmithkline, LLC. | $122.12 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $94.63 | 2021 | |
| Lundbeck LLC | $64.21 | 2022-2023 | Vyepti |
| Ucb, INC. | $61.24 | 2021 | |
| Lilly USA, LLC | $47.44 | 2019 | |
| Pfizer INC. | $39.81 | 2019 | |
| Horizon Therapeutics Plc | $33.26 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $33.22 | 2023 | |
| Celgene Corporation | $20.41 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $14.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Nardella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.